Belrestotug

Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity. Belrestotug can be used for cancer and immunological research such as colon cancer[1][2].

Product Specifications

CAS Number

2574438-65-4

Product Name Alternative

EOS-448; EOS884448; GSK4428859A

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/belrestotug.html

Purity

Solubility

H2O

Smiles

[Belrestotug]

Molecular Weight

(145.7 kDa)

References & Citations

[1]Cuende J, et al. a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME) [J]. medRxiv, 2025: 2025.07. 25.25332187. |[2]Cuende J, et al. Pharmacodynamic assessment of a-TIGIT mAb EOS-448 highlights multiple FcγR-mediated mode-of-actions in blood and tumor of patients with advanced solid tumors[J]. Cancer Res, 2022, 82 (12_Suppl) : LB189.